Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Last Updated: May 26, 2022

DrugPatentWatch Database Updates: New Patent Additions

✉ Email this page to a colleague

« Back to Dashboard

DrugPatentWatch Database Updates: New Patent Additions

These are patents which have been reported by the FDA since the last major update; they are not yet in the main database.

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign up for a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Number	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Requested	Patent Expiration	Date Submitted	Usecode	Patented / Exclusive Use
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE	200063	001	Sep 10, 2014	RX	Yes	See Plans and Pricing				See Plans and Pricing	2022-05-19	U-1583	FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER	214787	001	Oct 22, 2020	RX	Yes	See Plans and Pricing				See Plans and Pricing	2020-11-12	U-2984	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER	214787	002	Oct 22, 2020	RX	Yes	See Plans and Pricing				See Plans and Pricing	2020-11-12	U-2984	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER	214787	001	Oct 22, 2020	RX	Yes	See Plans and Pricing				See Plans and Pricing	2020-11-12	U-3249	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG)
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER	214787	002	Oct 22, 2020	RX	Yes	See Plans and Pricing				See Plans and Pricing	2020-11-12	U-3249	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG)
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER	214787	001	Oct 22, 2020	RX	Yes	See Plans and Pricing				See Plans and Pricing	2020-11-12	U-3367	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER	214787	002	Oct 22, 2020	RX	Yes	See Plans and Pricing				See Plans and Pricing	2020-11-12	U-3367	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Number	>Approval Date	>Type	>RLD	>Patent No.	>Product	>Substance	>Delist Requested	>Patent Expiration	>Date Submitted	>Usecode	>Patented / Exclusive Use

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt

Dow

Colorcon

McKesson

Boehringer Ingelheim

AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.